IMUX Strangle Strategy

IMUX (Immunic, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.

IMUX (Immunic, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $127.8M, a beta of 1.21 versus the broader market, a 52-week range of 5.06-15.1, average daily share volume of 309K, a public-listing history dating back to 2014, approximately 91 full-time employees. These structural characteristics shape how IMUX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.21 places IMUX roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.

What is a strangle on IMUX?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current IMUX snapshot

As of May 15, 2026, spot at $12.23, ATM IV 124.10%, IV rank 25.97%, expected move 35.58%. The strangle on IMUX below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this strangle structure on IMUX specifically: IMUX IV at 124.10% is on the cheap side of its 1-year range, which favors premium-buying structures like a IMUX strangle, with a market-implied 1-standard-deviation move of approximately 35.58% (roughly $4.35 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated IMUX expiries trade a higher absolute premium for lower per-day decay. Position sizing on IMUX should anchor to the underlying notional of $12.23 per share and to the trader's directional view on IMUX stock.

IMUX strangle setup

The IMUX strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With IMUX near $12.23, the first option leg uses a $12.84 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed IMUX chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 IMUX shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$12.84	N/A
Buy 1	Put	$11.62	N/A

IMUX strangle risk and reward

Net Premium / Debit: N/A
Max Profit (per contract): Unbounded
Max Loss (per contract): Unbounded
Breakeven(s): None on modeled curve
Risk / Reward Ratio: N/A

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

IMUX strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on IMUX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use strangle on IMUX

Strangles on IMUX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the IMUX chain.

IMUX thesis for this strangle

The market-implied 1-standard-deviation range for IMUX extends from approximately $7.88 on the downside to $16.58 on the upside. A IMUX long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current IMUX IV rank near 25.97% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on IMUX at 124.10%. As a Healthcare name, IMUX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to IMUX-specific events.

IMUX strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. IMUX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move IMUX alongside the broader basket even when IMUX-specific fundamentals are unchanged. Always rebuild the position from current IMUX chain quotes before placing a trade.

Frequently asked questions

What is a strangle on IMUX?: A strangle on IMUX is the strangle strategy applied to IMUX (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With IMUX stock trading near $12.23, the strikes shown on this page are snapped to the nearest listed IMUX chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are IMUX strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the IMUX strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 124.10%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a IMUX strangle?: The breakeven for the IMUX strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current IMUX market-implied 1-standard-deviation expected move is approximately 35.58%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on IMUX?: Strangles on IMUX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the IMUX chain.
How does current IMUX implied volatility affect this strangle?: IMUX ATM IV is at 124.10% with IV rank near 25.97%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.